PI3K/Akt/mTOR Signaling Pathway in Blood Malignancies—New Therapeutic Possibilities
Cancers · 05.11.2023 · 15 (21) · 5297
DOI: 10.3390/cancers15215297 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 05.11.2023. Verfasst von Wojciech Wiese und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Chemistry and Biochemistry, Medical University of Lodz, Mazowiecka 5, 92-215 Lodz, Poland. Die Arbeit wurde bisher 73-mal zitiert (Crossref) und nennt 127 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Lodz, Poland, Polish National Science Centre (NCN).
Abstract (Originalsprache)
Blood malignancies remain a therapeutic challenge despite the development of numerous treatment strategies. The phosphatidylinositol-3 kinase (PI3K)/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway plays a central role in regulating many cellular functions, including cell cycle, proliferation, quiescence, and longevity. Therefore, dysregulation of this pathway is a characteristic feature of carcinogenesis. Increased activation of PI3K/Akt/mTOR signaling enhances proliferation, growth, and resistance to chemo- and immunotherapy in cancer cells. Overactivation of the pathway has been found in various types of cancer, including acute and chronic leukemia. Inhibitors of the PI3K/Akt/mTOR pathway have been used in leukemia treatment since 2014, and some of them have improved treatment outcomes in clinical trials. Recently, new inhibitors of PI3K/Akt/mTOR signaling have been developed and tested both in preclinical and clinical models. In this review, we outline the role of the PI3K/Akt/mTOR signaling pathway in blood malignancies’ cells and gather information on the inhibitors of this pathway that might provide a novel therapeutic opportunity against leukemia.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Chemistry and Biochemistry, Medical University of Lodz, Mazowiecka 5, 92-215 Lodz, Poland.
- Department of Pathology, Fox Chase Cancer Center, Temple University, Philadelphia, PA 19111, USA.
- Faculty of Medicine, Cardinal Stefan Wyszyński University, 01-938 Warsaw, Poland.
ORCID-Profile: Wojciech Wiese, Julia Barczuk, Natalia Siwecka, Wioletta Rozpedek-Kaminska
Förderung
- Medical University of Lodz, Poland
- Polish National Science Centre (NCN)
Zitieren
APA
Wiese, W., Barczuk, J., Racinska, O., Siwecka, N., Rozpedek-Kaminska, W., Slupianek, A., Sierpinski, R., & Majsterek, I. (2023). PI3K/Akt/mTOR Signaling Pathway in Blood Malignancies—New Therapeutic Possibilities. Cancers, 15(21), 5297. https://doi.org/10.3390/cancers15215297
Vancouver
Wiese W, Barczuk J, Racinska O, Siwecka N, Rozpedek-Kaminska W, Slupianek A, et al. PI3K/Akt/mTOR Signaling Pathway in Blood Malignancies—New Therapeutic Possibilities. Cancers. 2023;15(21):5297. doi:10.3390/cancers15215297
BibTeX
@article{Wiese2023,
author = {Wiese, Wojciech and Barczuk, Julia and Racinska, Olga and Siwecka, Natalia and Rozpedek-Kaminska, Wioletta and Slupianek, Artur and Sierpinski, Radoslaw and Majsterek, Ireneusz},
title = {PI3K/Akt/mTOR Signaling Pathway in Blood Malignancies—New Therapeutic Possibilities},
journal = {Cancers},
year = {2023},
volume = {15},
number = {21},
pages = {5297},
doi = {10.3390/cancers15215297}
}
EUVIMED